Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates
Anti-CD22 Immunotherapeutics in:
October 2016 R&D and Business Tracker for Antibody-Drug Conjugates
This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates.
Featured presentations of October 2016 include the pipeline of CD22-targeted immunotherapeutics, the profile of US biotech Asana Biosciences and the profile of anti-nectin-6 antibody-drug conjugate AGS67E from Astellas Pharma.
The October 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:
R&D and Technology Tracker
Scientific Publication Tracker
Featured ADC Profile: AGS67E
Featured Company Profile: Asana Biosciencess
Featured Target Pipeline: Anti-CD22 Immunotherapeutics
CD-22Targeted Immunotherapeutics include:
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
October 2016 R&D and Business Tracker for Antibody-Drug Conjugates
This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates.
Featured presentations of October 2016 include the pipeline of CD22-targeted immunotherapeutics, the profile of US biotech Asana Biosciences and the profile of anti-nectin-6 antibody-drug conjugate AGS67E from Astellas Pharma.
The October 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
- Manufacturing news
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
Scientific Publication Tracker
Featured ADC Profile: AGS67E
Featured Company Profile: Asana Biosciencess
Featured Target Pipeline: Anti-CD22 Immunotherapeutics
CD-22Targeted Immunotherapeutics include:
- Naked Antibodies & Combinations
- Radioimmunotherapeutics
- Immunotoxins
- Antibody-Drug Conjugates
- Autologous CAR T-Cells
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
